NBIX Neurocrine Biosciences Inc.

+1.6  (+2%)
Previous Close 77.31
Open 77.17
Price To Book 14.92
Market Cap 7166706179
Shares 90,821,267
Volume 993,802
Short Ratio
Av. Daily Volume 1,317,784

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation 2Q/3Q 2019.
Congenital Adrenal Hyperplasia (CAH) - children
Phase 2a data due 1Q 2019.
Congenital Adrenal Hyperplasia (CAH) - adults
Approval for sNDA 80 mg capsules announced October 5, 2017.
Tardive dyskinesia
NDA filing planned for 2Q 2019.
Parkinson's disease
Phase 2 top-line data released December 12, 2018 did not meet primary endpoint.
Tourette syndrome - juvenile
Phase 2 data released January 18, 2017 did not meet primary endpoint.
Tourette syndrome - adults
NDA filing due 2019.
Uterine Fibroids
FDA approval announced July 24, 2018.
Approved April 11, 2017.
Tardive dyskinesia
Phase 2 data due late-2019.
Tourette syndrome - pediatric

Latest News

  1. Voyager Therapeutics stock jumps on 2nd Parkinson's deal
  2. Edited Transcript of NBIX earnings conference call or presentation 5-Feb-19 9:30pm GMT
  3. CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?
  4. See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
  5. Neurocrine Biosciences Inc (NBIX) Files 10-K for the Fiscal Year Ended on December 31, 2018
  6. The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering
  7. Neurocrine Biosciences Inc (NBIX) Q4 2018 Earnings Conference Call Transcript
  8. Neurocrine Biosciences (NBIX) Beats Q4 Earnings Estimates
  9. Neurocrine: 4Q Earnings Snapshot
  10. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results
  11. Neurocrine Biosciences, Inc. to Host Earnings Call
  12. The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results
  13. Here are Boston-area biotechs pursuing Parkinson's treatments
  14. Here's Why Voyager Therapeutics Stock Soared as Much as 62.9% Today
  15. Why Is Voyager Therapeutics Soaring Today?
  16. Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
  17. Neurocrine Biosciences and Voyager Therapeutics Form Strategic Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia
  18. Will Neurocrine Biosciences Continue to Surge Higher?
  19. Analysis: Positioning to Benefit within Neurocrine Biosciences, CONMED, TripAdvisor, Ryder System, Nordstrom, and Express — Research Highlights Growth, Revenue, and Consolidated Results